Progressive Multifocal Leukoencephalopathy as a Complication of Disease-modifying Treatment of Multiple Sclerosis


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

The review provides modern understanding of the pathogenesis of progressive multifocal leukoencephalopathy (PML), a severe and potentially fatal form of multiple-lesion disorder of the brain white matter. Information about the frequency of its development in patients with disease-modifying treatment of multiple sclerosis is analyzed. The algorithms of optimization of PML risks in this category of patients with multiple sclerosis are described in detail. Summarized are the data on most significant PML biomarkers, the search for which is currently under way in many centers across the world. The first case of PML in Russia is briefly described.

作者简介

M. Zakharova

Research Center of Neurology

Email: lysogorskaya@neurology.ru
俄罗斯联邦, Moscow

E. Lysogorskaia

Research Center of Neurology

编辑信件的主要联系方式.
Email: lysogorskaya@neurology.ru
俄罗斯联邦, Moscow

M. Ivanova

Research Center of Neurology

Email: lysogorskaya@neurology.ru
俄罗斯联邦, Moscow

I. Kochergin

Research Center of Neurology

Email: lysogorskaya@neurology.ru
俄罗斯联邦, Moscow

Y. Korzhova

Research Center of Neurology

Email: lysogorskaya@neurology.ru
俄罗斯联邦, Moscow

补充文件

附件文件
动作
1. JATS XML

版权所有 © Pleiades Publishing, Inc., 2019